Progressive liver impairment as a predictor of reduced survival in individuals with EGFR-mutated non-small cell lung cancer and liver metastases undergoing treatment with EGFR tyrosine kinase inhibitors - Summary - MDSpire
Advertisement
Progressive liver impairment as a predictor of reduced survival in individuals with EGFR-mutated non-small cell lung cancer and liver metastases undergoing treatment with EGFR tyrosine kinase inhibitors
To evaluate the prognostic significance of Consecutive Liver Function Abnormality (CLFA), defined as sustained liver function test abnormalities, in patients with EGFR-mutant NSCLC and liver metastases receiving first-line EGFR-TKIs.
Key Findings:
Patients with CLFA exhibited significantly reduced overall survival (OS) and progression-free survival (PFS) (p < 0.05).
The presence of CLFA was associated with increased hepatic tumor burden and poorer treatment response.
Dynamic changes in liver function during treatment were more predictive of outcomes than baseline liver function alone.
Interpretation:
CLFA serves as a dynamic biomarker indicating hepatic vulnerability and may guide risk stratification in patients with liver metastases undergoing EGFR-TKI therapy, potentially influencing treatment decisions.
Limitations:
The study's retrospective design may introduce selection bias.
The findings are limited to a single institution and may not be generalizable to broader populations.
Potential confounding factors, such as concurrent medications and comorbidities, were not fully controlled.
Conclusion:
Monitoring liver function abnormalities during EGFR-TKI treatment can provide valuable prognostic information and may help optimize management strategies for patients with liver metastases, ultimately improving patient outcomes.
